Introduction: Inflammatory breast cancer (IBC) represents a particular clinical entity characterized by its rarity, rapid evolutionary pace and pejorative prognosis. This was a retrospective descriptive study from January 01, 2020 to June 30, 2022 in the clinical oncology-hematology service of CHU B. This study included 62 patients with inflammatory breast cancer. The diagnosis of IBC was clinical as defined by the American Joint Cancer Committee (AJCC) with a diagnosis of anatomopathological confirmation. IBC accounted for 37.57% of breast cancers reported during our study period. The average age of patients was 47 years. The age range of [40 years-50] represented 37.09% followed by those of [50 years-60 years] and [60 years-70] with each 19.35%. The average consultation time was 12 months. Signs of inflammation were found in all patients followed by the presence of nodules during clinical examination. Infiltrating ductal carcinoma accounted for 95% of cases followed by infiltrating lobular carcinoma in 3%. Modified Scarff Bloom Richardson grade II (mSBR) was encountered in 93.5% of cases followed by mSBR grade III with 6.5%. Only 11 patients (17.74%) were able to perform immunohistochemistry. Thus, the results found 43% and 23% respectively of type luminal A and luminal B and 23% classified type Triple negative. Chemotherapy was performed in 51 patients (82.25%) and was palliative in 32 patients (62.74%). Ten (10) patients underwent surgery including 9 mastectomies with axillary dissection (90%). Radiotherapy was performed in 02 patients (3.22%). Median survival was 05 months and overall survival at 12 months was 23%. Finally, IBC is a fairly common pathology according to this study and affects especially young women under 50 years. Its management is complex by the fact that specific examinations and anti-cancer are difficult to access.
| Published in | International Journal of Clinical Oncology and Cancer Research (Volume 8, Issue 4) |
| DOI | 10.11648/j.ijcocr.20230804.12 |
| Page(s) | 88-93 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Inflammatory Breast Cancer, Profile, Burkina Faso
| [1] | Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72 (1): 7–33. |
| [2] | Slaoui M, Zoure AA, Mouh FZ, Bensouda Y, Mzibri M El, Bakri Y, et al. Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO). BMC Cancer. 2018; 1–9. |
| [3] | Mamouch F, Berrada N, Aoullay Z, El Khanoussi B, Errihani H. Inflammatory Breast Cancer: A Literature Review. World J Oncol. 2018; 9 (5–6): 129–35. |
| [4] | Brahm SA, Ziani FZ. Cancer du sein inflammatoire. Pan Afr Med J. 2016; 23: 1–2. |
| [5] | Overmoyer B, Pierce LJ. Inflammatory breast cancer. Dis Breast Fifth Ed. 2014; 60 (6): 351–75. |
| [6] | Tarek A, El-sayed SK, Woodward WA, El-shinawi M, Hirshon JM, Mohamed MM. Inflammatory Breast Cancer: The Cytokinome of Post-Mastectomy Wound Fluid Augments Proliferation, Invasion, and Stem Cell Markers. 2022; 2730–44. |
| [7] | Boussen H, Bouzaiene H, Hassouna J Ben, Dhiab T, Khomsi F, Benna F, et al. Inflammatory breast cancer in Tunisia: Epidemiological and clinical trends. Cancer. 2010; 116 (SUPPL. 11): 2730–5. |
| [8] | Scott L, Mobley LR, Il’Yasova D. Geospatial analysis of inflammatory breast cancer and associated community characteristics in the United States. Int J Environ Res Public Health. 2017; 14 (4): 1–10. |
| [9] | Roge M, Salleron J, Kirova Y, Guigo M, Huguet F, Nebbache R, et al. Étude Raibeca: radiotherapy for inflammatory breast cancer. Cancer/Radiothérapie. 25 (6–7): 740–1. |
| [10] | Mejri N, Benna H El, M’Ghirbi F, Labidi S, Daoud N, Boussen H. Biological features of inflammatory breast cancer in North Africa: Burden and research priorities. Breast Cancer Manag. 2018; 7 (2). |
| [11] | Bouzbid S, Aouras H. Le cancer du sein inflammatoire au centre hospitalo-universitaire d’Annaba, Algérie. Rev Epidemiol Sante Publique [Internet]. 2014; 62: S215–6. Available from: http://dx.doi.org/10.1016/j.respe.2014.06.142 |
| [12] | Jean-Bernard NM, Augustin Tozoula B, Donatien M, Gombé-Mbalaw C. Caractéristiques cliniques et évolutives des cancers du sein inflammatoires à Brazzaville. Bull Cancer. 2015; 100 (2). |
| [13] | Toure M, Nguessan E, Bambara AT, Kouassi YKK, Dia JML, Adoubi I. Facteurs liés au diagnostic tardif des cancers du sein en Afrique-sub-saharienne: Cas de la Cote d’Ivoire. Gynecol Obstet Fertil. 2013; 41 (12): 696–700. |
| [14] | Dia JM, Djanhan LE, Saki C, Oyéladé M, Okon G, Camara A, et al. Management of Inflammatory Breast Cancers in Subsaharian Africa Context. Open J Obstet Gynecol. 2018; 08 (01): 20–30. |
| [15] | DJIGUIMDE P. Les cancers inflammatoires du sein de la fapeutiqueemme: aspect épidémiologiques, cliniques et thérs dans trois structures sanitaires de la ville de ouagadougou: à propos de 45 cas. Université Joseph Ki-Zerbo. Joseph KI ZERBO University; 2012. |
| [16] | Dessaint A. Cancer du sein inflammatoire non métastatique: à propos d’une série rétrospective de 140 patientes traitées à l’Institut Bergonié entre 1989 et 2010 [Internet]. UB - Université de Bordeaux; 2015. Available from: https://dumas.ccsd.cnrs.fr/dumas-01212384v1 |
| [17] | Dano D, Lardy-Cleaud A, Monneur A, Quenel-Tueux N, Levy C, Mouret-Reynier MA, et al. Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME). ESMO Open. 2021; 6 (4). |
| [18] | Benbrahim Z, Berrada A, Amaadour L, Zahra El M’rabet F, Elfatemi H, Elfakir S, et al. Comparative study of inflammatory and non-inflammatory locally advanced breast cancer – the experience of a Moroccan hospital. Gynecol Obstet Fertil Senol. 2017; 45 (11): 604–8. |
| [19] | Schairer C, Li Y, Frawley P, Graubard BI, Wellman RD, Buist DSM, et al. Risk factors for inflammatory breast cancer and other invasive breast cancers. J Natl Cancer Inst. 2013; 105 (18): 1373–84. |
| [20] | Aloulou S, El Mahfoudi A, El Omrani A, Khouchani M. Facteurs liés au diagnostic tardif du cancer du sein: Expérience du chu mohammed vi marrakech. Pan Afr Med J. 2015; 21: 1–5. |
| [21] | Perou CM, Sørile T, Eisen MB, Van De Rijn M, Jeffrey SS, Ress CA, et al. Molecular portraits of human breast tumours. Nature. 2000; 406 (6797): 747–52. |
| [22] | Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, et al. International consensus on the clinical management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer research program 10th anniversary conference. J Cancer. 2018; 9 (8): 1437–47. |
| [23] | Binyom PR, Zaré HBGL, Fouelifack YF, Bwéllé G, Bang A, Ngowé Ngowé AM. Cancer Du Sein Inflammatoire Chez La Femme Camerounaise. Eur Sci J ESJ. 2020; 16 (36): 285–95. |
APA Style
Hierrhum Aboubacar, B., Abdou Azaque, Z., Nina Assanatou Jumelle, Z., Prisca Emmanuelle Aida, Y., Marc Donald Wilfried, A., et al. (2023). Epidemiological, Diagnostic, Therapeutic and Evolutionary Profile of Inflammatory Breast Cancer (IBC) in the Oncology-Hematology Service, Burkina Faso. International Journal of Clinical Oncology and Cancer Research, 8(4), 88-93. https://doi.org/10.11648/j.ijcocr.20230804.12
ACS Style
Hierrhum Aboubacar, B.; Abdou Azaque, Z.; Nina Assanatou Jumelle, Z.; Prisca Emmanuelle Aida, Y.; Marc Donald Wilfried, A., et al. Epidemiological, Diagnostic, Therapeutic and Evolutionary Profile of Inflammatory Breast Cancer (IBC) in the Oncology-Hematology Service, Burkina Faso. Int. J. Clin. Oncol. Cancer Res. 2023, 8(4), 88-93. doi: 10.11648/j.ijcocr.20230804.12
AMA Style
Hierrhum Aboubacar B, Abdou Azaque Z, Nina Assanatou Jumelle Z, Prisca Emmanuelle Aida Y, Marc Donald Wilfried A, et al. Epidemiological, Diagnostic, Therapeutic and Evolutionary Profile of Inflammatory Breast Cancer (IBC) in the Oncology-Hematology Service, Burkina Faso. Int J Clin Oncol Cancer Res. 2023;8(4):88-93. doi: 10.11648/j.ijcocr.20230804.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijcocr.20230804.12,
author = {Bambara Hierrhum Aboubacar and Zoure Abdou Azaque and Zerbo Nina Assanatou Jumelle and Yameogo Prisca Emmanuelle Aida and Adico Marc Donald Wilfried and Odero-Marah Valérie},
title = {Epidemiological, Diagnostic, Therapeutic and Evolutionary Profile of Inflammatory Breast Cancer (IBC) in the Oncology-Hematology Service, Burkina Faso},
journal = {International Journal of Clinical Oncology and Cancer Research},
volume = {8},
number = {4},
pages = {88-93},
doi = {10.11648/j.ijcocr.20230804.12},
url = {https://doi.org/10.11648/j.ijcocr.20230804.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20230804.12},
abstract = {Introduction: Inflammatory breast cancer (IBC) represents a particular clinical entity characterized by its rarity, rapid evolutionary pace and pejorative prognosis. This was a retrospective descriptive study from January 01, 2020 to June 30, 2022 in the clinical oncology-hematology service of CHU B. This study included 62 patients with inflammatory breast cancer. The diagnosis of IBC was clinical as defined by the American Joint Cancer Committee (AJCC) with a diagnosis of anatomopathological confirmation. IBC accounted for 37.57% of breast cancers reported during our study period. The average age of patients was 47 years. The age range of [40 years-50] represented 37.09% followed by those of [50 years-60 years] and [60 years-70] with each 19.35%. The average consultation time was 12 months. Signs of inflammation were found in all patients followed by the presence of nodules during clinical examination. Infiltrating ductal carcinoma accounted for 95% of cases followed by infiltrating lobular carcinoma in 3%. Modified Scarff Bloom Richardson grade II (mSBR) was encountered in 93.5% of cases followed by mSBR grade III with 6.5%. Only 11 patients (17.74%) were able to perform immunohistochemistry. Thus, the results found 43% and 23% respectively of type luminal A and luminal B and 23% classified type Triple negative. Chemotherapy was performed in 51 patients (82.25%) and was palliative in 32 patients (62.74%). Ten (10) patients underwent surgery including 9 mastectomies with axillary dissection (90%). Radiotherapy was performed in 02 patients (3.22%). Median survival was 05 months and overall survival at 12 months was 23%. Finally, IBC is a fairly common pathology according to this study and affects especially young women under 50 years. Its management is complex by the fact that specific examinations and anti-cancer are difficult to access.
},
year = {2023}
}
TY - JOUR T1 - Epidemiological, Diagnostic, Therapeutic and Evolutionary Profile of Inflammatory Breast Cancer (IBC) in the Oncology-Hematology Service, Burkina Faso AU - Bambara Hierrhum Aboubacar AU - Zoure Abdou Azaque AU - Zerbo Nina Assanatou Jumelle AU - Yameogo Prisca Emmanuelle Aida AU - Adico Marc Donald Wilfried AU - Odero-Marah Valérie Y1 - 2023/12/06 PY - 2023 N1 - https://doi.org/10.11648/j.ijcocr.20230804.12 DO - 10.11648/j.ijcocr.20230804.12 T2 - International Journal of Clinical Oncology and Cancer Research JF - International Journal of Clinical Oncology and Cancer Research JO - International Journal of Clinical Oncology and Cancer Research SP - 88 EP - 93 PB - Science Publishing Group SN - 2578-9511 UR - https://doi.org/10.11648/j.ijcocr.20230804.12 AB - Introduction: Inflammatory breast cancer (IBC) represents a particular clinical entity characterized by its rarity, rapid evolutionary pace and pejorative prognosis. This was a retrospective descriptive study from January 01, 2020 to June 30, 2022 in the clinical oncology-hematology service of CHU B. This study included 62 patients with inflammatory breast cancer. The diagnosis of IBC was clinical as defined by the American Joint Cancer Committee (AJCC) with a diagnosis of anatomopathological confirmation. IBC accounted for 37.57% of breast cancers reported during our study period. The average age of patients was 47 years. The age range of [40 years-50] represented 37.09% followed by those of [50 years-60 years] and [60 years-70] with each 19.35%. The average consultation time was 12 months. Signs of inflammation were found in all patients followed by the presence of nodules during clinical examination. Infiltrating ductal carcinoma accounted for 95% of cases followed by infiltrating lobular carcinoma in 3%. Modified Scarff Bloom Richardson grade II (mSBR) was encountered in 93.5% of cases followed by mSBR grade III with 6.5%. Only 11 patients (17.74%) were able to perform immunohistochemistry. Thus, the results found 43% and 23% respectively of type luminal A and luminal B and 23% classified type Triple negative. Chemotherapy was performed in 51 patients (82.25%) and was palliative in 32 patients (62.74%). Ten (10) patients underwent surgery including 9 mastectomies with axillary dissection (90%). Radiotherapy was performed in 02 patients (3.22%). Median survival was 05 months and overall survival at 12 months was 23%. Finally, IBC is a fairly common pathology according to this study and affects especially young women under 50 years. Its management is complex by the fact that specific examinations and anti-cancer are difficult to access. VL - 8 IS - 4 ER -
UFR/SDS, Joseph KI-ZERBO University, Ouagadougou, Burkina Faso; Clinical Hematology Oncology Service, CHU Bogodogo, Ouagadougou, Burkina Faso
Information